Martin J. Sadowski, MD, PhD, DSci is a Tenured Professor of Neurology, Psychiatry, and Biochemistry and Molecular Pharmacology at the New York University (NYU) Grossman School of Medicine and the Director of the Alzheimer Clinical Trial Program at NYU. Dr. Sadowski specializes in medical care of patients with Alzheimer disease and other forms of dementia and conducts translational and clinical research on Alzheimer disease therapeutics.
Dr. Sadowski received MD/PhD degree from the Medical University of Gdansk, in Gdansk, Poland. He completed postdoctoral fellowship in experimental neuropathology under the mentorship of Dr. Henry M. Wisniewski in the New York State Institute for Basic Research on Staten Island, NY and then residency in adult neurology at the NYU Medical Center in New York. Dr. Sadowski joined the faculty of the NYU School of Medicine in 2002. Dr. Sadowski attends patients with mild cognitive impairment, Alzheimer disease, fronto-temporal dementia, and other age-related neurodegenerative diseases. He also leads the NYU Alzheimer Clinical Trial Program and is the Principal Investigator of the Laboratory for Alzheimer Disease Therapeutics within the Department of Neurology. Research in Dr. Sadowski’s laboratory focuses on Aβ metabolism, apolipoprotein E, and discovery of novel therapeutics for Alzheimer disease and prion diseases. His research has been supported by the funding from National Institute on Aging, American Federation for Aging Research, Fisher Center for Alzheimer’s Research Foundation, Alzheimer’s Association, and private philanthropy. Dr. Sadowski has been recipient of the Markey’s Career Development Award, the Paul B. Beeson Career Development Award in Aging Research, and the NIA K02 Independent Scientist Award. He has authored over 130 papers in the field of Alzheimer disease, holds three US patents on Alzheimer therapeutics, and has served on numerous NIH advisory panels. Dr. Sadowski has been the Principal Investigator for over 40 Alzheimer clinical trials at the NYU Grossman School of Medicine and has served on Scientific Advisory Boards for American Foundation for Aging Research, Eisai, Biogen, Eli Lilly, Genentech, and Glaxo-Smith-Kline providing his expertise on the development of Alzheimer’s disease therapeutics.
